Paper40887107
HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions.
Okuyama K and 2 others. J Immunother Cancer, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions. Papers, record 40887107. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40887107
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Squamous Cell Carcinoma of Head and Neck | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Papillomavirus Infections | Major topic |
| Papillomaviridae | Major topic |
| Humans |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27718784 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718784 | PubMed |
| 2 | 17548594 | Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. | J Immunol | 2007 | https://conductscience.org/library/papers/17548594 | PubMed |
| 3 | 35727629 | Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. | J Clin Invest | 2022 | https://conductscience.org/library/papers/35727629 | PubMed |
| 4 | 36459926 | Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation. | Semin Immunol | 2023 | https://conductscience.org/library/papers/36459926 | PubMed |
| 5 | 37790755 | Cell-in-cell structure in cancer: evading strategies from anti-cancer therapies. | Front Oncol | 2023 | https://conductscience.org/library/papers/37790755 | PubMed |
| 6 | 39049036 | Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. | J Transl Med | 2024 | https://conductscience.org/library/papers/39049036 | PubMed |
| 7 | 31679945 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. | Lancet | 2019 | https://conductscience.org/library/papers/31679945 | PubMed |
| 8 | 38942993 | Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38942993 | PubMed |
| 9 | 40143171 | Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40143171 | PubMed |
| 10 | 26373277 | FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. | Cancer Cell | 2015 | https://conductscience.org/library/papers/26373277 | PubMed |
| 11 | 27777979 | The head and neck cancer immune landscape and its immunotherapeutic implications. | JCI Insight | 2016 | https://conductscience.org/library/papers/27777979 | PubMed |
| 12 | 34083421 | Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34083421 | PubMed |
| 13 | 35803260 | Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. | Cell | 2022 | https://conductscience.org/library/papers/35803260 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42482991 | Targeting innate immunity to overcome immune evasion in HPV-associated cancers. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42482991 | PubMed |
| 41815129 | Transmembrane protein 9 as a novel biomarker promotes oral squamous cell carcinoma growth via IL1RN and serves as an immune therapeutic target. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41815129 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FCGR1A | 2209 | PubTator's text mining | https://conductscience.org/library/genes/2209 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40887107
GET https://conductscience.org/api/papers/v1/40887107/authors